Kymera Therapeutics, Inc.
Company Stats
- Market Cap
- $9.3B
- as of Sep 30, 2026
- Shares Outstanding
- 83.2M
- Free Float
- 69.7%
Income Statement
- Revenue
- $39.2M
- Operating Income
- -$349.4M
- Net Income
- -$311.4M
- EBITDA
- -$341.1M
- Non-cash Impairment
- $3.9M
- Revenue Growth, 3Y
- -5.7%
- FCF Margin, 3Y Avg
- -404.3%
- FCF Margin, Worst Year
- -597.6%
Cash Flow
- Free Cash Flow
- -$234.3M
- FCF Yield
- -2.5%
- Owner FCF Yield
- -3.2%
Balance Sheet
- Cash & Equivalents
- $357.0M
Returns & Capital
- SBC, 3Y Avg
- $52.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $39.2M | -$234.3M | -597.6% |
| FY2024 | $47.1M | -$207.3M | -440.5% |
| FY2023 | $78.6M | -$137.3M | -174.7% |
| FY2022 | $46.8M | -$155.9M | -333.0% |
| FY2021 | $72.8M | -$130.5M | -179.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
AI Infrastructure Capital Floods In While Biotech Trials Split